725 filings
Page 10 of 37
4
f6i3bvqj ojf38
18 May 22
KEMPHARM / R. LaDuane Clifton ownership change
5:17pm
8-K
07780
16 May 22
KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline
8:40am
DEFA14A
gw5291zznt0y9t 04
12 May 22
Additional proxy soliciting materials
5:26pm
8-K
u9f58 fso9xnl7wq
12 May 22
KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates
4:48pm
8-K
zdoea4kv58oszb0mz
30 Mar 22
KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates
4:36pm
8-K
r4ncm33wrzp7kltkx
21 Mar 22
KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial
8:49am
8-K
kz4 3s73eoq8p4g52m
16 Mar 22
KemPharm team provided development and regulatory services to Corium pursuant to a master development services agreement
8:32am
8-K
axhy6bn70muaeio
22 Feb 22
Regulation FD Disclosure
9:09am
SC 13G
wk0bow25jybtd
4 Feb 22
KEMPHARM / BlackRock ownership change
4:12pm
4
1h53t
3 Feb 22
KEMPHARM / Timothy J. Sangiovanni ownership change
5:17pm
4
2yttvepzvz5mxf
3 Feb 22
KEMPHARM / Sven Guenther ownership change
5:17pm
4
onux4ceg4t6
3 Feb 22
KEMPHARM / R. LaDuane Clifton ownership change
5:15pm
4
mjvznr47m1onxn qgdk1
3 Feb 22
KEMPHARM / Richard W Pascoe ownership change
5:14pm
4
qbbe wvnzk02oaa191
3 Feb 22
KEMPHARM / Travis C Mickle ownership change
5:12pm
424B3
7j8hu1q4fofthhzqk5d
2 Feb 22
Prospectus supplement
4:16pm
EFFECT
nrzuga2ogq 8t7cz2fp6
2 Feb 22
Notice of effectiveness
12:15am
POS EX
mhlq9u
28 Jan 22
Additional exhibits for listing
6:15am